161 related articles for article (PubMed ID: 38134458)
1. Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers.
Lashen A; Al-Kawaz A; Jeyapalan JN; Alqahtani S; Shoqafi A; Algethami M; Toss M; Green AR; Mongan NP; Sharma S; Akbari MR; Rakha EA; Madhusudan S
Neoplasia; 2024 Jan; 47():100957. PubMed ID: 38134458
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
4. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
5. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
7. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
[TBL] [Abstract][Full Text] [Related]
8. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
[TBL] [Abstract][Full Text] [Related]
9. RECQL: a new breast cancer susceptibility gene.
Banerjee T; Brosh RM
Cell Cycle; 2015; 14(22):3540-3. PubMed ID: 26125302
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of germline mutations in breast cancer genes: RECQL.
Bowden AR; Tischkowitz M
Breast Cancer Res Treat; 2019 Apr; 174(3):553-560. PubMed ID: 30610487
[TBL] [Abstract][Full Text] [Related]
11. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
12. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
13. Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer.
Sun J; Wang Y; Xia Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Lou H; Xie Y
PLoS Genet; 2015 May; 11(5):e1005228. PubMed ID: 25945795
[TBL] [Abstract][Full Text] [Related]
14. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
Kim M; Choi HY; Woo JW; Chung YR; Park SY
Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
[TBL] [Abstract][Full Text] [Related]
15. Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
Xu H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
BMC Cancer; 2018 Jun; 18(1):662. PubMed ID: 29914420
[TBL] [Abstract][Full Text] [Related]
16. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
[TBL] [Abstract][Full Text] [Related]
17. Germline RECQL mutations in high risk Chinese breast cancer patients.
Kwong A; Shin VY; Cheuk IWY; Chen J; Au CH; Ho DN; Chan TL; Ma ESK; Akbari MR; Narod SA
Breast Cancer Res Treat; 2016 Jun; 157(2):211-215. PubMed ID: 27125668
[TBL] [Abstract][Full Text] [Related]
18. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.
Allred DC; Wu Y; Mao S; Nagtegaal ID; Lee S; Perou CM; Mohsin SK; O'Connell P; Tsimelzon A; Medina D
Clin Cancer Res; 2008 Jan; 14(2):370-8. PubMed ID: 18223211
[TBL] [Abstract][Full Text] [Related]
19. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer.
Afghahi A; Forgó E; Mitani AA; Desai M; Varma S; Seto T; Rigdon J; Jensen KC; Troxell ML; Gomez SL; Das AK; Beck AH; Kurian AW; West RB
Breast Cancer Res; 2015 Aug; 17(1):108. PubMed ID: 26265211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
